Nuveen’s GT Biopharma GTBP Stock Holding History

Nuveen’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,362	Closed	-$204K	–	3351
2022 Q1	$204K	Buy	2,362 +27	+1%	+$2.38K	﹤0.01%	3190
2021 Q4	$213K	Sell	2,335 -290	-11%	-$43.4K	﹤0.01%	3229
2021 Q3	$613K	Sell	2,625 -113	-4%	-$34K	﹤0.01%	3128
2021 Q2	$1.27M	Buy	+2,738	New	+$1.14M	﹤0.01%	2917

Other funds holding GTBP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

AWS

Atria Wealth Solutions New York $4.42B AUM 16.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's GTBP Position: Q2 2022 in Review

Nuveen sold out of GT Biopharma (GTBP) in Q2 2022, closing a stake of 2,362 shares — an estimated $204K sold.

Nuveen first reported a position in GTBP in Q2 2021 and held it in 4 quarters. The position peaked at $1.27M in Q2 2021. 47 funds tracked by Wall St. Rank hold GTBP as of Q2 2022.

Nuveen reported no remaining GT Biopharma position as of Q2 2022 after selling out during the quarter.
Nuveen sold 2,362 GT Biopharma shares in Q2 2022, an estimated $204K.
Nuveen first reported a position in GT Biopharma in Q2 2021 and held it in 4 quarters.
Nuveen's GT Biopharma position peaked at $1.27M in Q2 2021.
47 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.